2021
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
Park KU, Gregory M, Bazan J, Lustberg M, Rosenberg S, Blinder V, Sharma P, Pusztai L, Shen C, Partridge A, Thompson A. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Research And Treatment 2021, 188: 249-258. PMID: 33651271, PMCID: PMC7921279, DOI: 10.1007/s10549-021-06153-3.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionNeoadjuvant endocrine therapyMedical oncologistsRadiation oncologistsOmission of ALNDEstrogen positive breast cancer patientsPositive breast cancer patientsEarly-stage breast cancerEndocrine therapy useMetastatic axillary diseaseLymph node dissectionBreast cancer patientsMultidisciplinary tumor boardStage breast cancerClinical trial organizationsPercent of practicesUS medical oncologistsCOVID-19 pandemicPre-pandemic timesRegional COVID-19 casesAxillary diseaseMicrometastatic nodesSurgery 2Endocrine therapyLocoregional management
2018
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR
Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A. Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. Journal Of Cancer Research And Clinical Oncology 2018, 144: 601-606. PMID: 29344722, DOI: 10.1007/s00432-017-2574-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansMiddle AgedNeoadjuvant TherapyPreoperative PeriodRetrospective StudiesTamoxifenTreatment OutcomeConceptsAnthracycline-based chemotherapyNeoadjuvant chemotherapyHormone receptor-positive breast cancer patientsHormone receptor positive BC patientsReceptor-positive breast cancer patientsHormone receptor-positive BCHormone receptor-positive patientsNeoadjuvant anthracycline-based chemotherapyPathological complete response ratePositive breast cancer patientsReceptor-positive patientsComplete response rateUse of chemotherapyLuminal B tumorsBreast cancer patientsPositive BC patientsCombination of tamoxifenCombination of chemotherapyAddition of tamoxifenSmall patient populationProbability of benefitCremona HospitalEndocrine therapyHormonal therapyNeoadjuvant treatment